Kornimate/medical-research-clean huggingface dataset:
usefulness of endocuff in the adenoma detection rate. comparative study

Conditions: Colorectal Canceer

Summary: colorectal cancer (crc) is one of the leading causes of cancer death worldwide. the cumulative risk of developing crc is about 6% lifelong. the benefit of screening colonoscopy depends on the detection and removal of all adenomas, however, some of these may be difficult to detect. the "endocuff" (ec) is a polymer sleeve which joins the tip of the colonoscope to improve the image viewing of the mucosa during colonoscopy procedure. there is insufficient evidence of the usefulness of endocuf

all patients requiring colonoscopy for screening and who agree to participate in the study will be included and randomized them to make an standard colonoscopy or colonoscopy with endocuff, for randomization system will be used in balanced blocks of 4, created on the page randomization.com.

Eligibility criteria:
inclusion criteria: * healthy adult patients, * aged 18, * who would come to colonoscopy for colon cancer screening without prior colonoscopy studies exclusion criteria: * boston colonic preparation \<5 points * suspected lynch syndrome or familial adenomatous polyposis (fap)

Keywords: adenoma colonoscopy screening
a study of galcanezumab (ly2951742) in participants with migraine headache

Conditions: Migraine Headache

Summary: the main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.


Eligibility criteria:
inclusion criteria: * participants with a history of migraine of at least 1 year prior to enrollment. * migraine onset prior to age 50. exclusion criteria: * current enrollment in, or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device. * current use or any prior exposure to any cgrp antibody, any antibody to the cgrp receptor, or antibody to nerve growth factor (ngf). * history of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine, and basilar-type migraine. * have a history or presence of other medical illness that indicates a medical problem that would preclude study participation. * failure to respond to more than two adequately dosed effective migraine prevention treatments. * evidence of significant active psychiatric disease, in the opinion of the investigator. * women who are pregnant or nursing.
effects of induced moderate hypothermia on mortality in cardiogenic shock patients rescued by veno-arterial extracorporeal membrane oxygenation (ecmo)

Conditions: Cardiogenic Shock

Summary: a multicenter, prospective, controlled, randomized (moderate hypothermia 33°c≤ t°c ≤34°c) during 24 hours ± 1h versus normothermia (36°c≤ t°c ≤37°c), comparative open trial will be conducted on two parallel groups of patients with cardiogenic shock treated with va-ecmo. the hypo-ecmo trial will test the hypothesis that moderate hypothermia (temperature between 33°c≤ t°c ≤34°c) associated with va-ecmo support results in a reduction in 30-day mortality in comparison with the normothermia group (36°c≤ t°c ≤37°c).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * intubated patients with cardiogenic shock treated with va-ecmo * patient affiliated to social security plan exclusion criteria: * va-ecmo after cardiac surgery for heart transplantation or lung transplantation or left or biventricular assist device implantation * va-ecmo for acute poisoning with cardio-toxic drugs * pregnancy * uncontrolled bleeding (bleeding despite medical intervention (surgery or drugs)) * implantation of va ecmo under cardiac massage with a duration of cardiac massage \>45minutes * out of hospital refractory cardiac arrest * cerebral deficit with fixed dilated pupils * participation in another interventional research involving therapeutic modifications * patient moribund on the day of randomization * irreversible neurological pathology * minor patients * patients under tutelage

Keywords: venous-arterial extracorporeal membrane oxygenation
implementation of a protocol utilizing adaptive crt in a normal av conduction, crt non-response population at generator replacement

Conditions: Heart Failure

Summary: improve response is a physician initiated research study. it is a prospective, non-randomized, multi-center, post-market, u.s. cardiac resynchronization therapy (crt) in heart failure (hf) observational study. the purpose of this clinical study is to test the hypothesis that market-released crt devices, which contain the adaptivcrt (acrt) algorithm have an incremental benefit in improving crt response in a chronic crt non responder population with left bundle branch block (lbbb) and normal atrio-ventricular (av) condition compared to crt devices with traditional biventricular pacing delivery methods at generator replacement.


Eligibility criteria:
inclusion criteria: * normal av conduction (sav\<220 ms or pav\<270 ms) * left bundle branch block (defined as \> or = to 140 ms (male) or \> or = 130 (female), qr or rs in leads v1 and v2, and mid qrs notching or slurring in v 2 of leads v1, v2, v5, v6 and i and avl.) * patient and/or physician assessment or unchanged or worsened heart failure status at the time of recommended replacement time (rrt) for previous crt device. * sinus rhythm at the time of enrollment exclusion criteria: * moderate to severe aortic stenosis * moderate to severe mitral regurgitation * patient age \<18 years old * af burden \>15% * severe pulmonary disease requiring supplemental oxygen use * esrd * system modification at rrt generator changeout * adaptivcrt prior to enrollment * expected patient longevity \< 1 year * persistant or chronic atrial fibriliation * women who are pregnant or who plan to become pregnant during the clinical trial

Keywords: heart failure crt cardiac recynchronization therapy left bundle branch block atrio-ventricular conduction
shared medical decision making in the prophylactic treatment of bipolar disorder

Conditions: Bipolar Disorder

Summary: the investigators hypothesize that implementation of a shared decision making care plan for prophylactic treatment will help therapeutic adherence of bipolar patients. they also anticipate that patients treated according to a shared decision making plan will have an elevated satisfaction of their care, quality of life and functionment, as well as a lower number of relapses


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan * the patient must be available for the 12 months of follow-up * the patient is at least 18 years old * patients is suffering from bipolar disorder (i or ii) according to dsm-5 criteria * following resolution of a mood episode (manic or depressive according to dsm-5 criteria) according to the criteria of l'international society for bipolar disorder (recovery, clinical remission of at least 4 weeks) * followed by at least one of the practitioner belonging to one of the participating centers * without comprehension problems of fluent french exclusion criteria: * the subject is participating in an interventional study, or has participated in another interventional study within the previous 3 months * the subject is in a period of exclusion determined by a previous study * the patient is under safeguard of justice or state guardianship * it is impossible to give the subject informed information, or the subject refuses to sign the consent * the subject has already participated in this study * the patient has troubles linked to the usage of severe intensive substances (such as those defined by the dms-5) * the patient has a revision of the initial diagnosis of bipolar disorder
rct of an acceptance-based behavior therapy for gad

Conditions: Generalized Anxiety Disorder

Summary: the purpose of this study is to determine whether acceptance-based behavior therapy for gad results in greater symptom reduction and increased quality of life than applied relaxation.


Eligibility criteria:
inclusion criteria: * principal diagnosis of gad * at least moderate (4 on a scale from 0 to 8) on the adis severity scale for gad symptoms * willing to maintain current psychotropic medication levels (and have been stabilized on any current medications for at least three months) and refrain from other psychosocial treatments for anxiety or mood problems during the course of therapy * fluent in english * 18 years or older exclusion criteria: * bipolar disorder * psychotic disorders * substance dependence * active suicidal intent * if anxious symptomatology is due to a medical/physical condition
coronary artery geometry and the severity of coronary atherosclerosis

Conditions: Coronary Artery Disease; Atherosclerosis; Atherosclerotic Plaque; Stable Angina

Summary: the purpose of this study is to investigate the potential association of coronary artery geometry, based on coronary ct angiography (ccta), with the complexity and the severity of coronary atherosclerosis.

the angulation of the side branch take-off has been reported to influence the severity of atherosclerosis in coronary bifurcations, as larger angles have been associated with increased plaque burden. data from computational fluid dynamics studies have confirmed this finding by demonstrating that even in the absence of alterations in the amount of branch flow, a wide angle between the side branches intensifies flow perturbations, increases the spatial endothelial shear stress (ess) variations in the bifurcation region and the low ess in the lateral walls, thereby augmenting the atherosclerosis-prone environment. the magnitude of reversed flow, the extension of the recirculation zone and the duration of flow separation during the pulse cycle comprise other haemodynamic parameters which are important in atherogenesis and are amplified by an increased bifurcation angle.

Eligibility criteria:
inclusion criteria: * patients referred for cardiac ct angiography * patients without previous history of coronary artery disease (cad) * age ≥ 18 years * patients giving voluntary written consent to participate in the study exclusion criteria: * pregnancy or breast-feeding * patients with serious concurrent disease and life expectancy of \< 1 year * patients with a previous history of cad * patients who refuse to give written consent for participation in the study

Keywords: geometry bifurcation angle cardiac computed tomography angiography coronary artery disease vulnerable coronary plaque indexed coronary volume risk assessment
establishment of virtual reality system for stroke patients with aphasia

Conditions: Aphasia

Summary: aphasia can significantly influence a person's social relationship and quality of life. to achieve positive language outcomes, an intensive and high-repetition speech therapy is essential. however, due to the limited number of speech therapists, the intensity and frequency of training are often insufficient. therefore, it is critical to develop other rehabilitation approaches to enhance the benefits of aphasia intervention. virtual reality (vr) is an immersive and interactive computer simulation technology that can promote the ecological validity of speech therapy. in this study, we develop an innovative vr software for speech training to explore the effects of vr on various aspects of language outcomes.

we randomly assigned study participants into 2 groups: the traditional speech therapy (st) group and the traditional st with additional vr training (st+vr) group. in the st group, each participant received 1-hour traditional st for each session. in the st+vr group, an additional 30-minute vr training was administered immediately after each session of traditional st. all participants received 3 sessions of treatment every week for 3 weeks. for outcome measurement, we administered concise chinese aphasia test (ccat) at 3 different time points: before treatment, 1 day and 3 months after the completion of treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke with aphasia, including fluent and non-fluent types * age between 20\~80-year-old * able to understand virtual reality training * able to cooperate with instructions and follow the rules * able to use the virtual reality controller and device * able to sign the subject's informed consent exclusion criteria: * diagnosis of brain pathology other than stoke, such as brain tumor, parkinson's disease, dementia * unable to cooperate with the instructions * unable to learn how to use the virtual reality controller and device * any medical diseases or unstable vital signs that may cause safety concern * severe hearing or vision impairments * have ever received any form of speech therapy or virtual reality training

Keywords: virtual reality aphasia language rehabilitation stroke
the effect of breast milk smell on nutrition in preterms

Conditions: Breast Milk; Digestion; Nutrition; Smell Stimulation; Preterm Birth

Summary: the study was planned to determine the effect of breast milk odor applied during gavage feeding on early feeding cues of preterm newborns, the transition time to oral feeding and abdominal perfusion.

it is known that nutrient odors stimulate the initiation of digestion. however, in preterm newborns who are fed by gavage or parenterally, exposure to the nutrient smell that initiates digestion disappears. for this reason, it is known that odor stimulation is applied to preterm newborns to improve nutrition. it is known that fragrances such as fragrant essential oils, the smell of breast milk, and amniotic fluid have positive effects such as shortening the transition time to oral feeding in preterm newborns, increasing nutritional tolerance and weight gain, increasing hunger symptoms, providing analgesic effect in painful procedures, and reducing hospital stay. however, no study was found to jointly evaluate the effect of odor stimulation with breast milk on early nutritional cues, transition time to oral nutrition and abdominal perfusion in preterm newborns.

Eligibility criteria:
inclusion criteria: * born at 28-36 weeks of pw * birth weight \>1000 gr * 1. and 5. apgar score average per minute ≥ 6 * gavage method used in nutrition * intermittent infusion method used in nutrition, * not receiving mechanical ventilation / cpap support, * no medication or treatment is administered by the nasal route, * without nasal obstruction, * have not received any established medical diagnosis exclusion criteria: * drugs that affect gastrointestinal function (drugs that facilitate gastric emptying and gastrointestinal passage of nutrients by increasing gastrointestinal tract motility, and drugs that reduce gastrointestinal tract motility) * newborns without breast milk * continuous infusion or parenteral feeding method is used in nutrition

Keywords: breast milk abdominal perfusion preterm newborn smell stimulation feeding
effect of laser puncture on rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: studying the effect of laser puncture on rheumatoid arthritis patients


Eligibility criteria:
inclusion criteria: * meeting the criteria of acr classification for rheumatoid arthritis * meeting the criteria of eular classification for rheumatoid arthritis exclusion criteria: * having malignancy * having connective tissue disease * smokers
a safety and efficacy study of onabotulinumtoxina in upper facial rhytides

Conditions: Facial Rhytides; Glabellar Rhytides

Summary: this is a safety and efficacy study of onabotulinumtoxina in subjects with upper facial rhytides (forehead lines, glabellar lines, lateral canthal lines \[crow's feet lines\]).


Eligibility criteria:
inclusion criteria: * moderate to severe forehead lines, glabellar lines, and crow's feet lines * willing to have facial photos taken exclusion criteria: * prior exposure to botulinum toxin of any serotype for any indication * anticipated need for treatment with botulinum toxin of any serotype for any indication during the study, other than study treatment * diagnosis of myasthenia gravis, eaton-lambert syndrome, or amyotrophic lateral sclerosis * any facial resurfacing laser or light treatment, microdermabrasion, or superficial peels in the past 3 months * any medium depth or deep depth facial chemical peels; facial skin resurfacing; or permanent facial make-up in the past 6 months * any nonpermanent soft tissue fillers, or treatment with oral retinoids in the past year - prior face lift, thread lift, eyebrow lift, or related procedures (eg, eyelid and/or eyebrow surgery) * prior facial treatment with permanent soft tissue fillers, synthetic implants (eg, gore-tex®), and/or fat transplantation
alpha-lipoic acid in critically ill patients with sepsis

Conditions: Sepsis

Summary: evaluate the of effect of alpha-lipoic acid in critically ill septic patients. 60 septic patients will be enrolled from damanhur national medical institute, and they will be randomized using simple randomization into control group will receive placebo and ala group will be given 1800 mg orally or via a nasogastric tube of ala daily for seven days .

1. ethical committee approval will be obtained from ethics committee of faculty of pharmacy, damanhour university \& ethics committee of damanhur national medical national institute. 2. all participants or their relatives should agree to take part in this clinical study and will provide informed consent. 3. 60 septic patients will be enrolled from damanhur national medical institute, and they will be randomized using simple randomization into control group will receive placebo and ala group will be given 1800 mg orally or via a nasogastric tube of ala daily for seven days . 4. statistical tests appropriate to the study design will be conducted to evaluate the significance of the results. 5. results, conclusion, discussion and recommendations will be given. outcomes 1. the primary outcome icu and hospital mortality, icu and hospital stay, new acute kidney injury in icu, demand and duration of life support, sequential organ failure assessment (sofa)/acute physiology and chronic health evaluation ii (apache ii) 2. the secondary outcome are as follows: a. 28-day all-cause mortality b. change in inflammatory markers such as crp , il6, and tnf alpha and may be measured glycocalyx degradation markers such as syndecan 1.

Eligibility criteria:
inclusion criteria: * patients who will be diagnosed with sepsis or develop sepsis during their icu length of stay * age 18 year and older * patient able to receive oral or enteral medication exclusion criteria: * patients who will be diagnosed with septic shock * female patients who are pregnant or lactating. * participation in another clinical trial. * current treatment with other medications that have antioxidant effects, such as vitamin c and vitamin e. * allergy to la or similar active agents (e.g., vitamin b), or previous intolerance to the recommended dose of la
combination antibiotic therapy for methicillin resistant staphylococcus aureus infection

Conditions: Methicillin-Resistant Staphylococcus Aureus

Summary: the aim of this clinical trial is to determine whether a novel combination antibiotic treatment (vancomycin/daptomycin + beta-lactam) is superior to the standard antibiotic treatment (vancomycin/daptomycin) for hospitalised adults with methicillin resistant staphylococcus aureus bacteraemia. the hypothesis is that the addition of beta-lactam antibiotics (these are antibiotics from the penicillin family) to the standard therapy will lead to more efficient bacterial killing and hence lead to faster clearance of bacteria from the blood stream and other areas of infection, thereby reducing the risk of the spread of infection and death. the study design is an investigator-initiated, multi-centre, open-label, randomised controlled trial. this will include 440 participants diagnosed with methicillin resistant staphylococcus aureus bacteraemia recruited over a period of 4 years (july 2015 - june 2019) from within infectious diseases inpatient units across 21 hospital sites including 18 from within australia and 3 located in singapore. participation will be voluntary and subject to informed consent. the participants will be randomised 1:1 to either the standard therapy group or combination therapy group. the combination therapy will include a treatment of intravenous beta-lactam for the first 7 days of treatment, in addition to the standard treatment (either vancomycin or daptomycin). the primary outcome measure will be complication-free survival 90 days post randomisation.


Eligibility criteria:
inclusion criteria: 1. age \>= 18 years. 2. ≥1 set of blood cultures positive for mrsa 3. able to be randomized within 72 hours of blood cultures being collected. 4. likely to remain as inpatient for 7 days following randomization exclusion criteria: 1. previous type 1 hypersensitivity reaction to ß-lactams 2. polymicrobial bacteraemia (not counting contaminants) 3. previous participation in the trial 4. known pregnancy 5. current β-lactam antibiotic therapy which cannot be ceased or substituted 6. participant's primary clinician unwilling to enrol patient 7. moribund (expected to die in next 48 hours with or without treatment) 8. treatment limitations which preclude the use of antibiotics note that we are not planning to exclude participants with renal failure.

Keywords: methicillin-resistant staphylococcus aureus (mrsa)
periapical healing in response to endodontically treated teeth with different sealing cement

Conditions: Apical Periodontitis

Summary: the goal of this clinical trial is to conduct an in vivo study that allows to compare the periapical healing process of 3 different sealing cements through cbct, as well as implement the evaluation of these lesions through volumetric measurements to provide high-level scientific information and thus have the possibility of being applied in the clinical dental practice, in patients attending unicoc dental clinics between 2023 and 2024. the main question it aims to answer is: * do bioceramic sealer promote faster periapical healing due to their better sealing capacity and high bio-compatibility? * are there no differences between endodontic sealers in terms of apical healing? if there is a comparison group: researchers will compare bio-c sealer (bioceramic sealer) zinc-oxide eugenol sealer and ah-plus epoxy resin sealer to evaluate periapical healing after a six months follow-up of conventional endodontic therapy. coronal permanent restoration must be performed no later than 15 days after endodontic therapy.


Eligibility criteria:
inclusion criteria: * patients aged 18 to 60 * patients systemically healthy (asa i) * patients that require endodontic therapy for single-rooted teeth with pulp necrosis and apical periodontitis (ap). * cbct pai periapical index score 3 or above, with no symptoms at the time of appointment. exclusion criteria: * exclusion criteria included other than asa-1 classification * patients with perforated cortical plates at cbct analysis * premature permanent teeth * patients with endodontic-periodontic lesions, dystrophic calcifications, more than 20° root curvature * pregnancy or lactation * root fracture cases * use of analgesics within 12-24 hours root canal therapy and patients with endodontic abscess.

Keywords: clinical trial endodontic sealer periapical healing